CPT code 96446 denotes the administration of chemotherapy into the peritoneal cavity using an implanted port or catheter. As a specialized locoregional oncology service, it captures procedures where cytotoxic or targeted agents are delivered directly into the abdomen, typically for peritoneal carcinomatosis or other intra-abdominal malignancies. This code matters nationally because it reflects a high-acuity, facility-based infusion procedure with implications for clinical workflow, device utilization, and payer coverage policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, where the service is typically performed, and which payers commonly adjudicate claims for this service. The publication provides benchmark-oriented content: how the service is classified, common billing modifiers, and typical sites of care. It also highlights policy and billing considerations relevant to hospitals and ambulatory infusion centers that provide intraperitoneal chemotherapy.

The report is intended for billing managers, oncology clinical leaders, and policy analysts seeking a clear reference on CPT code 96446, including operational context and the payer landscape. Data not available in the input is clearly noted where applicable.